Overview of each patient’s characteristics: part 1
| Pt . | Age, sex . | Underlying disease,* date of first leukemia diagnosis . | Systematic therapy shortly before and during COVID-19, date of therapy start . | Remission status after current therapy . | Relevant secondary diseases . | Duration of aplasia, d . | Admit to ICU/invasive ventilation (duration, d) . | SOFA score† at ICU admit/ max 72 h . | Severity of ARDS (Horovitz index) . | Complications during ICU stay . | Chest CT results per Simpson et al,6 total severity score per Li et al7 . | SARS-CoV-2 viremia at baseline and at day 14 of follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 34, M | Ph+ common B-ALL, 3/13/2020 | GMALL 8/13 trial: 1. Prephase: 3/13/20 2. Induction: 3/19/20 | MRD+ after induction I | None | None | Yes (13)/yes (4) | 2/9 | Severe (75) | Septic shock, DVT | Typical appearance, 10 | Baseline 3/18/20, yes; day 14, no |
| 2 | 76, M | De novo AML (intermediate risk), 3/6/20 | Induction 1: 3+7, 3/13/20 | Unknown (death) | Follicular thyroid carcinoma 2007 | 15 | Yes (12)/yes (8) | 11/12 | Severe (72) | Septic shock | Typical appearance, 8 | Baseline 3/18/20, yes; day 14, yes |
| 3 | 46, F | MRD+ Ph− common-B-ALL, 12/6/19 | Blinatumomab: 1. First cycle: 3/31/20 2. Second cycle: 5/12/20 | MRD− after first cycle, second cycle ongoing | Hypothyroidism, bronchial asthma, allergic rhinitis | None | No/NA | NA | NA | NA | Typical appearance, 5 | Baseline 4/6/20, ND; day 14, no |
| 4 | 64, F | T-ALL, 3/13/20 | GMALL recommendations for patients >55 y: 1. Prephase: 3/13/20 2. Induction 1: 3/19/20 3. Induction 2: 4/15/20 | CR after induction II | None | 4 | Yes (9)/no | 3/3 | No ARDS | None | ND | Baseline 4/5/20, yes; day 14, no |
| 5 | 47, M | De novo AML (favorable risk), 3/9/20 | AMLSG21-12 trial: 1. Induction 1: 3+7, 3/12/20 2. Consolidation 1: HDAC, 4/17/20 | 1. CRi after induction I 2. Unknown (death) | None | 7 | Yes (11)/yes (10) | 3/11 | Severe (55) | Septic shock, stroke, subarachnoid hemorrhage | Typical and indeterminate appearance, 19 | Baseline 4/5/20, yes; day 14, yes |
| 6 | 50, M | De novo AML (adverse risk), 2/19/20 | 1. Induction 1: 3+7 + midostaurin, 2/21/20 2. FLAG-Ida + sunitinib: 3/27/20 3. Aza and Ven: 5/2/20 | Refractory to 1. and 2. 3. Ongoing Aza/Ven treatment | None | 43 | Yes (5)/no | 4/5 | No ARDS | None | Typical appearance, 5 | Baseline 4/5/20, yes; day 14, no |
| 7 | 62, M | De novo AML (adverse risk), 4/2/20 | 1. First-cycle Aza and Ven: 4/7/20 | CRi | None | 7 | Yes (23)/yes (12) | 2/4 | Severe (85) | Septic shock | ND | Baseline 4/5/20, yes; day 14, yes |
| 8 | 60, M | Secondary AML,‡ 2/27/20 | 1. Induction 1: CPX351, 3/2/20 2. First-cycle Aza and Ven: 4/16/20 | Refractory after induction I and Aza/ Ven | Lung emphysema, smoker | 34 | Yes (3)/no | 5/6 | No ARDS | None | ND | Baseline 4/5/20, yes; day 14, no |
| 9 | 64, M | Therapy-associated AML, 2/27/20 | 1. Induction 1: refractory to CPX351, 3/2/20 2. First-cycle Aza and Ven: 4/7/20 | 1. Refractory after induction I 2. CRi | Primary CNS lymphoma 2010 | 36 | Yes (2)/no | 4/4 | No ARDS | None | Typical appearance, 6 | Baseline 4/5/20, yes; day 14, yes |
| 10 | 60, M | De novo AML (adverse risk), 3/5/20 | 1. Induction 3+7 + midostaurin: 3/9/20 2. First-cycle Aza and Ven: 4/14/20 | Refractory after induction I and Aza/Ven | None | 37 | Yes (9)/no | 3/4 | No ARDS | None | ND | Baseline 4/5/20, yes; day 14, no |
| 11 | 69, F | De novo AML (adverse risk), 4/2/20 | 1. First-cycle Aza and Ven: 4/3/20 2. Second-cycle Aza and Ven: 5/15/2020 | 1. CRi | None | 33 | Yes (8)/yes (4) | 5/13 | Severe (83) | Septic shock | ND | Baseline 4/1/20, yes; day 14, no |
| 12 | 32, M | Lymphoblastic TCL, 11/5/19 | GMALL 08/13 trial: reinduction, 4/16/20 | MRD+ after reinduction | None | None | No/NA | NA | NA | NA | ND | Baseline 4/9/20, ND; day 14, no |
| Pt . | Age, sex . | Underlying disease,* date of first leukemia diagnosis . | Systematic therapy shortly before and during COVID-19, date of therapy start . | Remission status after current therapy . | Relevant secondary diseases . | Duration of aplasia, d . | Admit to ICU/invasive ventilation (duration, d) . | SOFA score† at ICU admit/ max 72 h . | Severity of ARDS (Horovitz index) . | Complications during ICU stay . | Chest CT results per Simpson et al,6 total severity score per Li et al7 . | SARS-CoV-2 viremia at baseline and at day 14 of follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 34, M | Ph+ common B-ALL, 3/13/2020 | GMALL 8/13 trial: 1. Prephase: 3/13/20 2. Induction: 3/19/20 | MRD+ after induction I | None | None | Yes (13)/yes (4) | 2/9 | Severe (75) | Septic shock, DVT | Typical appearance, 10 | Baseline 3/18/20, yes; day 14, no |
| 2 | 76, M | De novo AML (intermediate risk), 3/6/20 | Induction 1: 3+7, 3/13/20 | Unknown (death) | Follicular thyroid carcinoma 2007 | 15 | Yes (12)/yes (8) | 11/12 | Severe (72) | Septic shock | Typical appearance, 8 | Baseline 3/18/20, yes; day 14, yes |
| 3 | 46, F | MRD+ Ph− common-B-ALL, 12/6/19 | Blinatumomab: 1. First cycle: 3/31/20 2. Second cycle: 5/12/20 | MRD− after first cycle, second cycle ongoing | Hypothyroidism, bronchial asthma, allergic rhinitis | None | No/NA | NA | NA | NA | Typical appearance, 5 | Baseline 4/6/20, ND; day 14, no |
| 4 | 64, F | T-ALL, 3/13/20 | GMALL recommendations for patients >55 y: 1. Prephase: 3/13/20 2. Induction 1: 3/19/20 3. Induction 2: 4/15/20 | CR after induction II | None | 4 | Yes (9)/no | 3/3 | No ARDS | None | ND | Baseline 4/5/20, yes; day 14, no |
| 5 | 47, M | De novo AML (favorable risk), 3/9/20 | AMLSG21-12 trial: 1. Induction 1: 3+7, 3/12/20 2. Consolidation 1: HDAC, 4/17/20 | 1. CRi after induction I 2. Unknown (death) | None | 7 | Yes (11)/yes (10) | 3/11 | Severe (55) | Septic shock, stroke, subarachnoid hemorrhage | Typical and indeterminate appearance, 19 | Baseline 4/5/20, yes; day 14, yes |
| 6 | 50, M | De novo AML (adverse risk), 2/19/20 | 1. Induction 1: 3+7 + midostaurin, 2/21/20 2. FLAG-Ida + sunitinib: 3/27/20 3. Aza and Ven: 5/2/20 | Refractory to 1. and 2. 3. Ongoing Aza/Ven treatment | None | 43 | Yes (5)/no | 4/5 | No ARDS | None | Typical appearance, 5 | Baseline 4/5/20, yes; day 14, no |
| 7 | 62, M | De novo AML (adverse risk), 4/2/20 | 1. First-cycle Aza and Ven: 4/7/20 | CRi | None | 7 | Yes (23)/yes (12) | 2/4 | Severe (85) | Septic shock | ND | Baseline 4/5/20, yes; day 14, yes |
| 8 | 60, M | Secondary AML,‡ 2/27/20 | 1. Induction 1: CPX351, 3/2/20 2. First-cycle Aza and Ven: 4/16/20 | Refractory after induction I and Aza/ Ven | Lung emphysema, smoker | 34 | Yes (3)/no | 5/6 | No ARDS | None | ND | Baseline 4/5/20, yes; day 14, no |
| 9 | 64, M | Therapy-associated AML, 2/27/20 | 1. Induction 1: refractory to CPX351, 3/2/20 2. First-cycle Aza and Ven: 4/7/20 | 1. Refractory after induction I 2. CRi | Primary CNS lymphoma 2010 | 36 | Yes (2)/no | 4/4 | No ARDS | None | Typical appearance, 6 | Baseline 4/5/20, yes; day 14, yes |
| 10 | 60, M | De novo AML (adverse risk), 3/5/20 | 1. Induction 3+7 + midostaurin: 3/9/20 2. First-cycle Aza and Ven: 4/14/20 | Refractory after induction I and Aza/Ven | None | 37 | Yes (9)/no | 3/4 | No ARDS | None | ND | Baseline 4/5/20, yes; day 14, no |
| 11 | 69, F | De novo AML (adverse risk), 4/2/20 | 1. First-cycle Aza and Ven: 4/3/20 2. Second-cycle Aza and Ven: 5/15/2020 | 1. CRi | None | 33 | Yes (8)/yes (4) | 5/13 | Severe (83) | Septic shock | ND | Baseline 4/1/20, yes; day 14, no |
| 12 | 32, M | Lymphoblastic TCL, 11/5/19 | GMALL 08/13 trial: reinduction, 4/16/20 | MRD+ after reinduction | None | None | No/NA | NA | NA | NA | ND | Baseline 4/9/20, ND; day 14, no |
3+7, daunorubicin 60 mg/m2, days 1, 3, and 5 plus cytarabine 100 mg/m2 days 1-7; admit, admission; aplasia, neutrophil count <0.5 × 109/L; Aza, azacytidine; CPX351, CPX351 100 U/m2 days 1, 3, and 5, azacitidine and venetoclax analog per DiNardo et al2 ; DVT, deep vein thrombosis; F, female; FLAG-Ida, fludarabine 30 mg/m2 days 1-4, cytarabine 2000 mg/m2 days 1-4, idarubicin 10 mg/m2 days 1 and 3; GMALL, German Multicentre ALL Study Group; HDAC, high-dose cytarabine, 2000 mg/m2 twice per day, days 1-3; ICU, intensive care unit; M, male; max, maximum; MRD, minimal residual disease; NA, not applicable; ND, not done; Ph, Philadelphia chromosome; Pt, patient; sunitinib, 25 mg/d ongoing; TCL, T-cell lymphoma; Ven, venetoclax.
AML risk stratification according to the European LeukemiaNet classification.11
SOFA score according to Singer et al.12
Preexisting myelodysplastic syndrome.